Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Ana Vivancos
Vall d’Hebron Institute of Oncology (VHIO)
Learn more about SSRN Profiles
SCHOLARLY PAPERS
2
DOWNLOADS
86
TOTAL CITATIONS
0
Feedback
Scholarly Papers (2)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
A Phase Ii, Open-Label, Randomized Trial of Durvalumab with Olaparib or Cediranib in Patients with Mismatch Repair–Proficient Colorectal or Pancreatic Cancer
Number of pages: 54
Posted: 14 Mar 2024
Alberto Hernando
,
Ming Han
,
Olubukola Ayodele
,
Ben X. Wang
,
Farnoosh Abbas-Aghababazadeh
,
Maria Vila-Casadesús
,
Enrique Sanz-García
,
S.Y. Cindy Yang
,
Hal Berman
, Ana Vivancos,
Bernard Lam
,
Ilinca Lungu
,
Abdulazeez Salawu
,
Lee-Anne Stayner
,
Benjamin Haibe-Kains
,
Philippe L. Bedard
,
Lisa Avery
,
Albiruni R. Abdul Razak
,
Trevor J. Pugh
,
Anna Spreafico
,
Lillian L. Siu
and
Aaron Hansen
Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Princess Margaret Cancer Centre, Vall d’Hebron Institute of Oncology (VHIO), Ontario Institute for Cancer Research, Ontario Institute for Cancer Research, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Tumor Immunotherapy Program, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre and University of Toronto - Princess Margaret Cancer Centre
Downloads
43
(1,157,785)
View PDF
Download
Abstract:
Immunotherapy, biomarkers, colorectal, pancreatic, cancer, cold tumors
2.
A Pan-Cancer Clinical Platform to Predict Immunotherapy Outcomes and Prioritize Immuno-Oncology Combinations in Early-Phase Trials
Number of pages: 34
Posted: 17 Feb 2023
Alberto Hernando
,
Maria Vila-Casadesús
,
Yacine Bareche
,
Alberto Gonzalez-Medina
,
Francesco Mancuso
,
Deborah Lo Giacco
,
Agatha Martin
,
Omar Saavedra
,
Irene Brana
,
Maria Vieito
,
Roberta Fasani
,
John Stagg
,
Farnoosh Abbas-Aghababazadeh
,
Benjamin Haibe-Kains
,
Roger Berche
,
Nadia Saoudi Gonzalez
,
Claudia Valverde
,
Eva Muñoz-Couselo
,
Cristina Suarez
,
Marc Diez
,
Maria Elena Elez
,
Jaume Capdevila
,
Ana Oaknin
,
Cristina Saura
,
Teresa Macarulla
,
Joan Carles Galceran
,
Enriqueta Felip
,
Rodrigo Dienstmann
,
Philippe L. Bedard
,
Paolo Nuciforo
,
Joan Seoane
,
Josep Tabernero
,
Josep Tabernero
,
Elena Garralda
and Ana Vivancos
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), University of Montreal - Faculté de Pharmacie, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Université de Montréal - Faculty of Pharmacy, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO)Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron Institute of Oncology (VHIO)
Downloads
43
(1,145,425)
View PDF
Download
Abstract:
Feedback